The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

@2024 - All Right Reserved.

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

RFH Healthcare Managing Director Maxwel Okoth addresses a past press breifing. [File, Standard] RFH Healthcare has announced a medical milestone with the successful administration of Lutetium therapy ...

Dr. Rohan Garje reviews the latest rapid recommendation update for the ASCO guideline on systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC). He reviews what prompted ...

Lu-177 dotatate is a molecular therapy. It is a type of peptide receptor radionuclide therapy (PRRT) used mainly for neuroendocrine tumors (NETs). PRRT combines a compound called a peptide with a ...

In men with newly diagnosed metastatic hormone-sensitive prostate cancer, adding lutetium-177 PSMA-617 (177 Lu-PSMA-617) to standard hormone therapy led to a statistically significant improvement in ...